一種新型口服的直接凝血酶抑制劑被設計用于更加迅速的可控制的發(fā)揮抗凝血效應，治療窗口得以改善，患者的治療反應可以預測，治療效能也更好。

最常見的血栓癥類型是發(fā)生在腿部的深靜脈血栓癥(DVT)。這種類型的血凝塊能夠破裂，通過腿和心臟，在肺部停留，導致動脈阻塞，這被稱為肺部栓塞。當前使用的治療這種疾病的藥物，是肝素和華法令，但是這兩種藥物都有缺陷。肝素需要靜脈用藥和監(jiān)測血壓。肝素導致的血小板減少，或者血小板計數(shù)下降，是醫(yī)院內最常見的嚴重藥物反應。另一方面，華法令的治療窗則非常小，能夠導致非常嚴重的藥物相互作用方面的問題。

這種新型抗凝血藥物叫做MPC-0920，是由Myriad Genetics公司(Salt Lake City, UT, USA)研制開發(fā)的，該公司指出其臨床前研究的資料已經(jīng)接近完成。“MPC-0920是一種很有前景的化合物，在治療領域十分重要。”  Myriad制藥公司總裁Adrian Hobden博士說，“我們期望能夠在這個財政年度，完成呈遞給美國食品藥品管理局的臨床前研究資料。”

Antithrombin Drug in Development
 
A new orally available, direct thrombin inhibitor is designed to provide more rapid and predictable anticoagulant action, an improved therapeutic window, predictable patient response, and better efficacy.

The most common type of thrombosis is deep-vein thrombosis (DVT) in the leg. This type of clot can break apart, travel up the leg and through the heart, and lodge in the lungs, causing blockage of an artery, known as pulmonary embolism. The drugs currently used to treat this condition are heparin and warfarin, but both have drawbacks. Heparin requires intravenous administration and blood-level monitoring. Heparin-induced thrombocytopenia, or low platelet count, is the most common serious drug reaction in hospitals. Warfarin, on the other hand, has a very small therapeutic window and its use can result in serious drug interaction problems.

The new antithrombin drug, MPC-0920, was developed by Myriad Genetics, Inc. (Salt Lake City, UT, USA), which notes that it is rapidly nearing completion of the preclinical data. “MPC-0920 is an intriguing compound in a vitally important therapeutic area,” said Adrian Hobden, Ph.D., president of Myriad Pharmaceuticals, Inc. “We look forward to completing the preclinical data package for submission to the FDA [U.S. Food and Drug Administration] this fiscal year.”